Wells Fargo upgraded Voyager Therapeutics to Overweight from Equal Weight with a $14 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis
- Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics selects development candidate for SOD1 program
- Voyager Therapeutics management to meet with Oppenheimer